NLM Digital Collections


Search Constraints

Start Over You searched for: Formats Text Remove constraint Formats: Text Copyright Public domain Remove constraint Copyright: Public domain Publication Year 2000 to 2023 Remove constraint Publication Year: <span class="from" data-blrl-begin="2000">2000</span> to <span class="to" data-blrl-end="2023">2023</span>

Search Results

1. Data inadequacies undermine CMS's oversight of the inconsistency resolution process for the federal marketplace

2. CMS validated hospital inpatient quality reporting program data, but should use additional tools to identify gaming

4. CDC generally met its inspection goals for the federal select agent program: however, opportunities exist to strengthen oversight

6. Round 2 competitive bidding for CPAP/RAD: disrupted access unlikely for devices, inconclusive for supplies

8. OHRP generally conducted its compliance activities independently, but changes would strengthen its independence

9. HHS's Office of Refugee Resettlement improved coordination and outreach to promote the safety and well-being of unaccompanied alien children

10. Medicare program shared savings accountable care organizations have shown potential for reducing spending and improving quality

13. As funding for BPA research increased, NIEHS followed its peer review process while also exercising its discretion

15. Medicare Part B drug payments: impact of price substitutions based on 2014 average sales prices

17. Drug supply chain security: wholesalers exchange most tracing information

22. Enhancements needed in the tracking and collection of Medicare overpayments identified by ZPICS and PSCS

23. A few states fell short in timely investigation of the most serious nursing home complaints: 2011-2015

25. Medicare Part B drug payments: impact of price substitutions based on 2015 average sales prices

26. Medicare payments for clinical diagnostic laboratory tests in 2016: year 3 of baseline data

27. Excluding noncovered versions when setting payment for two Part B drugs would have resulted in lower drug costs for Medicare and its beneficiaries

28. Medicaid Fraud Control Units: investigation and prosecution of fraud and beneficiary abuse in Medicaid personal care services

29. Followup review: CMS's management of the quality payment program

30. Potential misclassifications reported by drug manufacturers may have led to $1 billion in lost Medicaid rebates

31. Entities' experiences and perceptions of reporting the theft, loss, or release of select agents or toxins to CDC

32. Drug supply chain security: dispensers received most tracing information

34. Round two competitive bidding for oxygen: continued access for vast majority of beneficiaries

35. Round two competitive bidding for enteral nutrition: continued access for vast majority of beneficiaries

36. HRSA helped health centers with elevated risks and can continue to take additional steps

38. Part D plans generally include drugs commonly used by dual eligibles: 2018

40. Entities generally met Federal Select Agent Program internal inspection requirements, but CDC could do more to improve effectiveness

41. Opioid use in Medicare Part D remains concerning

42. CMS did not detect some inappropriate claims for durable medical equipment in nursing facilities

43. Opioids in Ohio Medicaid: review of extreme use and prescribing

46. Medicare Part B drug payments: impact of price substitutions based on 2016 average sales prices

47. Questionable billing for compounded topical drugs in Medicare Part D

48. FDA should further integrate its review of cybersecurity into the premarket review process for medical devices

49. Treatment planning and medication monitoring were lacking for children in foster care receiving psychotropic medication

50. Medicare payments for clinical diagnostic laboratory tests in 2017: year 4 of baseline data